Overview

Bortezomib Maintenance in High Risk DLBCL

Status:
Active, not recruiting

Trial end date:
2021-10-30

Target enrollment:

Participant gender:

Summary

This study is an Open-labeled, multicenter Phase II study of Bortezomib for maintenance therapy in patients with high risk diffuse large B cell lymphoma (DLBCL). Primary objective is 3 years relapse free survival (RFS) and Secondary objectives are 3 years overall survival (OS), 3 years event free survival (EFS),Toxicities profiles, Quality of Life (FACT&GOG-Ntx)

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Collaborator:

Janssen, LP

Treatments:

Bortezomib